Conference Paper: Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction

File Download

No File Attached
The HKU Scholars Hub has contact details for these author(s).

Supplementary

Citations:
- Scopus:
- Web of Science:
- PubMed Central:
Item Statistics (The Hub)
Appears in Collections:
- Medicine: Conference papers

Title	Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction
Authors	Wong, D Lai, CL Seto, WK Fung, J Huang, FY Hung, IFN Yuen, RMF
Keywords	Medical sciences Gastroenterology
Issue Date	2011
Publisher	Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation	The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754 [How to Cite?]
Abstract	BACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.
Description	This journal suppl. is Abstract Book of The International Liver Congress™ 2011 Posters
ISSN	0168-8278 2011 Impact Factor: 9.264 2011 SCImago Journal Rankings: 0.765

DC Field	Value
dc.contributor.author	Wong, D
dc.contributor.author	Lai, CL
dc.contributor.author	Seto, WK
dc.contributor.author	Fung, J
dc.contributor.author	Huang, FY
dc.contributor.author	Hung, IFN
dc.contributor.author	Yuen, RMF
dc.date.accessioned	2011-07-27T01:59:41Z
dc.date.available	2011-07-27T01:59:41Z
dc.date.issued	2011
dc.description.abstract	BACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.
dc.description	This journal suppl. is Abstract Book of The International Liver Congress™ 2011
dc.description	Posters
dc.description.other	The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754
dc.identifier.citation	The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754 [How to Cite?]
dc.identifier.epage	S303
dc.identifier.hkuros	188152
dc.identifier.hkuros	190367
dc.identifier.issn	0168-8278 2011 Impact Factor: 9.264 2011 SCImago Journal Rankings: 0.765
dc.identifier.issue	suppl. 1
dc.identifier.spage	S303
dc.identifier.uri	http://hdl.handle.net/10722/135917
dc.identifier.volume	54
dc.language	eng
dc.publisher	Elsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
dc.publisher.place	Netherlands
dc.relation.ispartof	Journal of Hepatology
dc.subject	Medical sciences
dc.subject	Gastroenterology
dc.title	Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction
dc.type	Conference_Paper

<?xml encoding="utf-8" version="1.0"?><item><contributor.author>Wong, D</contributor.author><contributor.author>Lai, CL</contributor.author><contributor.author>Seto, WK</contributor.author><contributor.author>Fung, J</contributor.author><contributor.author>Huang, FY</contributor.author><contributor.author>Hung, IFN</contributor.author><contributor.author>Yuen, RMF</contributor.author><date.accessioned>2011-07-27T01:59:41Z</date.accessioned><date.available>2011-07-27T01:59:41Z</date.available><date.issued>2011</date.issued><identifier.citation>The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754</identifier.citation><identifier.issn>0168-8278</identifier.issn><identifier.uri>http://hdl.handle.net/10722/135917</identifier.uri><description>This journal suppl. is Abstract Book of The International Liver Congress&#8482; 2011</description><description>Posters</description><description.abstract>BACKGROUND AND AIMS: Nucleos(t)ide analogues (NA) are effective in the reduction of HBV viral load. We aimed to investigate their 1 year effects on intrahepatic total HBVDNA and covalently closed circular DNA (cccDNA) levels. METHODS: We recruited from our center 124 patients who had baseline and year 1 liver biopsies and taken part in three phase III international clinical trials (BEHoLD [entecavir vs. lamivudine], GLOBE [telbivudine vs. lamivudine] and QUASH [clevudine vs. adefovir]). These NA were categorized into the more potent group (entecavir, telbivudine, and clevudine; 36 HBeAg-positive and 35 HBeAg-negative patients) and less potent group (lamivudine and adefovir; 31 HBeAg-positive and 22 HBeAg-negative patients). Intrahepatic HBV DNA and cccDNA were measured by real-time PCR. Serum HBV DNA was measured by the COBAS TaqMan HBV Monitor Test. RESULTS: After 1 year of NA therapy, in the HBeAg-positive patients, the more potent NA caused a greater mean reduction of serum HBV DNA than the less potent group (6.7 vs. 5.0 logs, respectively; P = 0.005). In the HBeAg-negative patients, there was no significant difference in serum HBV DNA reduction between the more potent and less potent groups (4.9 vs. 4.7 logs, respectively, P = NS). There were no significant differences between the more potent and less potent groups in the mean reduction of intrahepatic total HBV DNA (2.1 vs. 1.8 logs respectively in HBeAg-positive patients and 1.4 vs. 1.6 logs respectively in HBeAg-negative patients) and cccDNA (1.1 vs. 0.9 logs respectively in both HBeAg-positive and HBeAg-negative patients; all P = NS). Although 88/124 (71%) patients had undetectable serum HBV DNA at year 1, all patients had detectable intrahepatic total HBV DNA. Only five patients (all HBeAg-negative) had undetectable cccDNA after 1 year; nine patients had an increase in cccDNA. CONCLUSIONS: 71% of patients had undetectable serum HBV DNA after 1 year, but intrahepatic total HBV DNA and cccDNA, though reduced, were still detectable in the majority of patients. This suggests that even when highly potent NA are used, a longer term of NA therapy is needed to reduce intrahepatic HBV DNA.</description.abstract><language>eng</language><publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jhep</publisher><relation.ispartof>Journal of Hepatology</relation.ispartof><subject>Medical sciences</subject><subject>Gastroenterology</subject><title>Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction</title><type>Conference_Paper</type><identifier.hkuros>188152</identifier.hkuros><identifier.hkuros>190367</identifier.hkuros><identifier.volume>54</identifier.volume><identifier.issue>suppl. 1</identifier.issue><identifier.spage>S303</identifier.spage><identifier.epage>S303</identifier.epage><publisher.place>Netherlands</publisher.place><description.other>The 46th Annual Meeting of the European Association for the Study of the Liver (EASL 2011), Berlin, Germany, 30 March-3 April 2011. In Journal of Hepatology, v. 54 suppl. 1, p. S303, abstract no. 754</description.other></item>

Conference Paper: Efficacies of one year nucleos(t)ide analogue therapy in intrahepatic HBV DNA and covalently closed circular DNA reduction

The HKU Scholars Hub has contact details for these author(s).